INAB Stock Risk & Deep Value Analysis
IN8bio Inc
DVR Score
out of 10
What You Need to Know About INAB Stock
We analyzed IN8bio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INAB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
INAB Risk Analysis & Red Flags
What Could Go Wrong
With a pre-revenue status and a new at-the-market (ATM) sales agreement in place as of June 2026, IN8bio faces significant financial risk; a major clinical setback for its lead GBM program or slower-than-expected progress could necessitate rapid, highly dilutive capital raises, jeopardizing existing shareholder value and potentially pushing the company towards a going concern risk as highlighted in prior periods.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Completion of a 1-for-30 reverse stock split (reported by Robinhood), indicative of low stock price and potential listing concerns.
- ⚠
New at-the-market (ATM) sales agreement with JonesTrading (June 2026), signaling continued reliance on dilutive financing to fund operations.
- ⚠
Pre-revenue status with sustained operating losses (Q1 2026 GAAP EPS -$0.26), necessitating continuous external funding.
- ⚠
Absence of a confirmed positive outcome from the critical ASCO 2026 (June 1) clinical data presentation in the provided real-time intelligence.
- ⚠
Beneficial ownership transfer of 724,637 shares to a charitable foundation, causing reporting persons to cease being 5%+ beneficial owners as of May 27, 2026, indicating a reduction in a significant stakeholder's position.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for INAB-200 (GBM) in late 2026/early 2027, potentially leading to a 50%+ stock price decline and increased risk of program abandonment.
- 📅
Rapid cash depletion, leading to further highly dilutive equity raises or an inability to fund ongoing clinical trials by early 2027, exacerbating the 'going concern' risk and potentially halving the share price.
When to Reconsider
- 🚪
Exit if current clinical trial (INAB-200 or INAB-100) data is released and indicates a lack of efficacy or unacceptable safety profile, leading to a program discontinuation.
- 🚪
Sell if cash and equivalents (as reported in subsequent 10-Q filings) fall below $10 million without a clear, non-dilutive financing plan, signaling immediate liquidity crisis.
- 🚪
Exit if management announces additional highly dilutive equity offerings or another reverse stock split beyond the current ATM agreement.
Unlock INAB Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If IN8bio's allogeneic gamma-delta T-cell therapies, specifically INAB-200 for GBM, demonstrate compelling efficacy and safety data in subsequent clinical trials (e.g., meeting or exceeding pre-specified mOS endpoints in Phase 2), then the company could secure regulatory approval by 2029-2030, unlocking a multi-hundred-million-dollar annual revenue stream from a high-unmet-need market. This is bullish because the market currently prices the stock almost entirely on early-stage risk, offering substantial upside if clinical de-risking occurs.
Is INAB Stock Undervalued?
Unlock the full AI analysis for INAB
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
INAB Price Targets & Strategy
12-Month Target
$4.00
Bull Case
$15.40
Bear Case
$0.50
Valuation Basis
12-month target of $4.00 aligns with current analyst consensus, implicitly factoring early clinical pipeline progress. Upside scenario of $15.40 represents a 10x return based on successful Phase 2/3 trial data for lead assets and subsequent market leadership in GBM/AML, justified by a ~$250M valuation (10x current market cap) if the platform achieves initial market penetration.
Entry Strategy
Dollar-cost average on dips towards $1.00-$1.20, potentially below the recent 50-day SMA, to capitalize on volatility but avoid overpaying given the clinical-stage nature.
Exit Strategy
Consider profit-taking 50% of position between $4.00-$6.00 after significant positive clinical data or regulatory milestones. Implement a stop-loss at $0.80 if clinical setbacks or severe dilution become evident.
Portfolio Allocation
2% for aggressive risk tolerance, given the highly speculative, clinical-stage nature and significant financial risks.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is INAB Financially Healthy?
Valuation
P/E Ratio
-0.55
Price/Book
0.81
Profitability
Return on Equity
-96.39%
EPS
$-3.04
Balance Sheet
Current Ratio
8.82
Quick Ratio
8.65
Debt/Equity
0.01
Cash & Equivalents
$21.90M
Other
Beta (Volatility)
0.23
Does INAB Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is currently narrow and expanding based on the novelty and potential efficacy of their gamma-delta T-cell platform. Its durability depends heavily on successful clinical trials validating superior efficacy and safety, leading to regulatory approval and establishing a strong IP portfolio that is difficult for competitors to bypass. If clinical data is robust, it could become a significant standard of care in niche oncology markets.
Moat Erosion Risks
- •Clinical failure of lead candidates (INAB-200, INAB-100) would significantly erode IP value and competitive positioning.
- •Emergence of superior or cheaper competing allogeneic cell therapy platforms from larger pharmaceutical companies.
INAB Competitive Moat Analysis
Sign up to see competitive advantages
INAB Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to cautiously Bullish due to retail interest in high-risk biotech plays, but constrained by stock performance and dilution concerns.
Institutional Sentiment
Mixed. Analyst consensus target is $4.00, but with a distribution of 1 Sell, 1 Hold, 1 Buy, reflecting uncertainty. A prior price target decrease was noted (March 29, 2026 to $6.46, details not provided).
Insider Activity (Form 4)
No Form 4 insider buying or selling by CEO/CFO in the last 90 days was reported. Ms. Fairbairn beneficially owned 215,431 shares as of May 27, 2026. A significant beneficial owner group transferred 724,637 shares to a charitable foundation on May 27, 2026, ceasing to be 5%+ owners, which is a reduction in institutional-level holding.
Options Flow
Normal options activity; no specific data on unusual put/call ratios or large block trades was provided in the research.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 for Q2 2026 earnings.
Surprise Probability
Low, given pre-revenue status and binary nature of clinical updates often overshadowing quarterly financials.
Historical Earnings Pattern
For clinical-stage biotechs, stock price reaction is primarily driven by clinical and regulatory updates rather than quarterly financial results. Financials usually elicit strong negative reactions only if cash runway is significantly shorter than expected.
Key Metrics to Watch
Competitive Position
Top Competitor
Comparables like DWTX, KZR, BYSI operate in the broader biotech space but may not directly compete on allogeneic gamma-delta T-cells. There are several companies in the T-cell therapy space (autologous and allogeneic CAR-T/TCR-T), but IN8bio's specific focus on gamma-delta T-cells in GBM/AML creates a niche. Companies like Fate Therapeutics (FATE) are also in allogeneic cell therapy.
Market Share Trend
Not yet applicable, as the company is pre-commercial. Its goal is to establish market share upon regulatory approval.
Valuation vs Peers
As a clinical-stage, pre-revenue company, traditional valuation metrics like P/E are not applicable. It trades at a significant discount to larger clinical-stage biotechs with more advanced pipelines or broader platforms, reflecting its early stage and high risk.
Competitive Advantages
- •Proprietary allogeneic gamma-delta T-cell platform (off-the-shelf potential, less manufacturing complexity than autologous).
- •Focused clinical development in high-unmet-need areas like Glioblastoma (GBM) and Acute Myeloid Leukemia (AML).
- •Potential for improved safety and efficacy profile compared to traditional cell therapies, leveraging gamma-delta T-cells' unique biology.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive INAB Stock Higher?
Near-Term (0-6 months)
- •Updated clinical data presentation for INAB-200 (GBM) program from ASCO 2026 (June 1, 2026) via press release or investor update (GlobeNewswire June 3, 2026 press release content is pending verification), expected to include mean Overall Survival (mOS) data. Positive data could re-rate the stock by 50-100%.
- •Planned FDA discussions on regulatory pathways for INAB-200 in GBM, expected in H2 2026. A clear path to accelerated approval would significantly de-risk the program and could add $20-30M to valuation.
Medium-Term (6-18 months)
- •Initiation of pivotal Phase 2/3 trial for INAB-200 in GBM by mid-2027, signaling progression toward regulatory submission. This milestone, if funded, could trigger a re-rating by 100-200% on the prospect of future revenue.
- •Positive Phase 1 data from INAB-100 (AML) program in early 2027, validating the broad applicability and safety of the gamma-delta T-cell platform. Efficacy signals here could expand TAM perception, adding ~$50-100M to valuation.
Long-Term (18+ months)
- •Regulatory approval and commercial launch of INAB-200 for GBM by 2029-2030, projecting peak annual sales exceeding $500M within the first five years, leading to a potential market cap of $1-2 billion.
- •Successful expansion of gamma-delta T-cell platform into additional oncology indications or combination therapies by 2030+, establishing IN8bio as a leader in allogeneic cellular therapies and broadening its revenue base to over $1 billion annually.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for INAB?
- ✓
Watch for positive, quantified mOS data from INAB-200 (GBM) clinical updates; exceeding 12-month mOS for recurrent GBM patients would be a strong signal.
- ✓
Monitor cash burn rate in quarterly filings; a cash runway below 4 quarters without new financing would indicate severe financial distress.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How IN8bio Inc Makes Money
IN8bio is a clinical-stage biotechnology company focused on developing novel allogeneic (off-the-shelf) gamma-delta T-cell therapies to treat various cancers, primarily Glioblastoma (GBM) and Acute Myeloid Leukemia (AML). The company currently generates no revenue and incurs significant R&D and operational expenses to advance its drug candidates through preclinical and clinical development. Its business model relies on raising capital to fund these trials, with the ultimate goal of gaining regulatory approval for its therapies and then commercializing them through sales or licensing agreements, which would generate revenue and potentially profits.
Read Full Business Model BreakdownFAQ
What is the DVR Score for IN8bio Inc (INAB)?
As of June 3, 2026, IN8bio Inc has a DVR Score of 6.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of IN8bio Inc?
IN8bio Inc's market capitalization is approximately $15.4M..
What is the risk level for INAB stock?
Our analysis rates IN8bio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of INAB?
IN8bio Inc currently has a price-to-earnings (P/E) ratio of -0.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the INAB DVR analysis updated?
Our AI-powered analysis of IN8bio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INAB (IN8bio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.